Everything below concerns gastric juice protein. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Mitragotri has invented many novel drug delivery technologies, especially in the fields of transdermal, oral and targeted systems. He invented techniques to deliver drugs transdermally using low-frequency ultrasound, pulsed microjet injector, high throughput skin experimentation, skin penetrating peptides and ionic liquids. He also invented intestinal patches and ionic liquids for oral delivery of proteins. Mitragotri also pioneered nanoparticle-enabled cell therapies which use drug-loaded nanoparticles that hitch a ride on red blood cells, monocytes and other circulatory cells for tissue-specific delivery. Mitragotri's technologies are used to develop next generation therapies against diabetes, cancer, psoriasis, hemorrhage, trauma and infections. Mitragotri has published over 400 research publications and is an inventor on over 300 patents/applications. His publications are cited over 81000 times with an h-index of 140. Mitragotri is a member of the US National Academy of Medicine and the US National Academy of Inventors. He is also a member of the US National Academy of Engineering since 2015 for the development, clinical translation, and commercialization of transdermal drug delivery systems. He is also an elected member of The World Academy of Science , American Academy of Arts & Sciences and Indian National Academy of Engineering. He is a co-founder of several companies that are developing products based on his inventions. He received his PhD in chemical engineering at MIT and BS in chemical engineering from the Institute of Chemical Technology.
The first and most important measure was the founding of the Kingdom of Italy, proclaimed on 17 March 1861 with Victor Emmanuel II as constitutional monarch. The method of voting between the plebiscite and the parliamentary elections was different: in 1860 all male citizens who were at least 21 years of age and in possession of civil rights was able to vote, while the next round of elections was governed by Piedmontese electoral law, which was census-based and enfranchise only male citizens who were at least 25 years of age, able to read and write and who paid at least 40 liras in taxes. The narrower voting group elected many members of the aristocratic and upper middle class. This included many Calabrian patriots, such as Francesco Stocco and the brothers Antonino Plutino and Agostino Plutino, the historical right with liberal and conservative tendencies, and the historical left with progressive and democratic ideas.
== Variations == Other boneless chuck cuts include the chuck eye (boneless cuts from the center of the roll, sold as Delmonico steak or chuck eye steak), chuck fillet (sold as chuck tender steak or mock tender steak), cross-rib roast (sold as cross-rib pot roast, English roast, or "the bread and butter cut"), top blade steak or chicken steak, under-blade steak (otherwise known as the "Denver cut"), shoulder steak and shoulder roast, and arm steak and arm roast. The average meat market cuts thick and thin chuck steaks (often sold as chuck steak or chuck steak family pack) from the neck and shoulder, but some markets also cut it from the center of the cross-rib portion. Short ribs are cut from the lip of the roll. Some meat markets will sell cross-rib pot roast under the generic name pot roast. The difference between a pot roast and a cross-rib pot roast is the vertical line of fat separating the two types of chuck meat; the cross-rib pot roast contains the line of fat. This is what creates richness of flavor in the roast.
Sources: en.wikipedia.org
== Niobium-92 == Niobium-92 is an extinct radionuclide with a half-life of 34.7 million years, decaying predominantly via β+ decay. Its abundance relative to the stable 93Nb in the early Solar System, estimated at 1.7×10−5, has been measured to investigate the origin of p-nuclei. A higher initial abundance of 92Nb has been estimated for material in the outer protosolar disk (sampled from the meteorite NWA 6704), suggesting that this nuclide was predominantly formed via the gamma process (photodisintegration) in a nearby core-collapse supernova. Niobium-92, along with niobium-94, has been detected in refined samples of terrestrial niobium and may originate from bombardment by cosmic ray muons in Earth's crust.
females age 12 to 21 may have iron deficiency (27 June), researchers show how bird flu could mutate to overcome a human antiviral protein to start another pandemic (28 June), shortages of medications – including some against cancer – are reported across countries, articles in science outlets like Nature suggest contemporary viral concerns about hypothetical existential risk of AI "plays into the tech companies' agenda" – partly in the form of 'criti-hype' – and that this "hinders effective regulation of the societal harms AI is causing right now" and in the near-future. Promising results of therapeutic candidates are reported: first phase 3 trialed chikungunya vaccine (VLA1553) (12 June), mice-tested inoculation against a potential infectious contributor to endometriosis (14 June), new evidence regarding still-unclear vaginal seeding interventions (15 June), phase 2 trialed orforglipron against obesity (23 June), mice-tested gene-therapy against hearing loss (28 June).
In 2011, tourists visiting Ghana numbered 1,087,000, with arrivals including South Americans, Asians, Europeans, and North Americans. Among the attractions and tourist destinations are waterfalls such as Kintampo waterfalls and the largest waterfall in west Africa, Wli waterfalls, the coastal palm-lined sandy beaches, caves, mountains, rivers, and reservoirs and lakes such as Lake Bosumtwi and the largest human-made lake in the world by surface area, Lake Volta, dozens of forts and castles, World Heritage Sites, nature reserves and national parks. Castles include Cape Coast Castle and the Elmina Castle. Castles mark where blood was shed in the slave trade and preserve and promote the African heritage stolen and destroyed through the slave trade. The World Heritage Convention of UNESCO named Ghana's castles and forts as World Heritage Monuments: "The Castles and Forts of Ghana shaped not only Ghana's history but that of the world over four centuries as the focus of first the gold trade and then the slave trade. They are a significant and emotive symbol of European–African encounters and of the starting point of the African Diaspora." The World Economic Forum statistics in 2010 showed that out of the world's favourite tourist destinations, Ghana was ranked 108th out of 139 countries. The country had moved two places up from the 2009 rankings. In 2011, Forbes magazine published that Ghana was ranked the 11th most friendly country in the world. The assertion was based on a survey in 2010 of a cross-section of travellers.
Sources: en.wikipedia.org
=== Postoperative care === Postoperative care involves hand therapy and splinting. Hand therapy is prescribed to optimize post-surgical function and to prevent joint stiffness. The extent of hand therapy is depending on the patient and the corrective procedure. Besides hand therapy, many surgeons advise the use of static or dynamic splints after surgery to maintain finger mobility. The splint is used to provide prolonged stretch to the healing tissues and prevent flexion contractures. Although splinting is a widely used post-operative intervention, evidence of its effectiveness is limited, leading to variation in splinting approaches. Most surgeons use clinical experience to decide whether to splint. Cited advantages include maintenance of finger extension and prevention of new flexion contractures. Cited disadvantages include joint stiffness, prolonged pain, discomfort, subsequently reduced function and edema. A third approach emphasizes early self-exercise and stretching.
Whether this panacea contained the traditional ingredients such as opium, myrrh and hemp, is not known. In the Middle East, theriac was known as Tiryaq, and makers of it were known as Tiryaqi. In medieval London, the preparation arrived on galleys from the Mediterranean, under the watchful eye of the Worshipful Company of Grocers. Theriac, the most expensive of medicaments, was called Venice treacle by the English apothecaries. At the time of the Black Death in the mid 14th century, Gentile da Foligno, who died of the plague in June 1348, recommended in his plague treatise that the theriac should have been aged at least a year. Children should not ingest it, he thought, but have it rubbed on them in a salve. In 1669, the famous French apothecary, Moyse Charas, published the formula for theriac, seeking to break the monopoly held by the Venetians at that time on the medication, thereby opening up the transfer of medical information.
On 13 February 2007, HGS and GSK announced the initiation of the first of two Phase III clinical trials of belimumab in patients with active lupus erythematosus. Two Phase III clinical studies were conducted, involving a total of 1,684 patients with scores of ≥6 on the SELENA-SLEDAI assessment of lupus activity. The primary end point was a reduction of ≥4 on the SELENA-SLEDAI assessment, and several other factors, after 52 weeks. Belimumab significantly improved the response rate, reduced disease activity and severe flares, and was well tolerated. Among patients treated with belimumab (10mg/kg) in addition to standard therapy, 58% had SELENA-SLEDAI scores reduced by ≥4 points over 52 weeks, compared with 46% of patients treated with placebo. However, patients of African-American or African descent did not respond significantly to belimumab. These trials did not include patients with the most severe forms of systemic lupus erythematosus, which involve active damage to the kidneys or central nervous system. Subjects with active kidney disease were included in Phase II trials. Clinical trials found belimumab to be safe in treating systemic lupus erythematosus, but the magnitude of benefit was small, and Phase III trials excluded the most severe cases of systemic lupus erythematosus, involving kidney and brain damage. Reviewers at the US Food and Drug Administration (FDA) expressed concern that the drug was only "marginally" effective, and that there were more deaths in the treatment group.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.